Pyxis Oncology, Inc. Common Stock (PYXS) is a publicly traded Healthcare sector company. As of October 27, 2026, PYXS trades at $1.69 with a market cap of $140.13M and a P/E ratio of -1.57. PYXS moved +0.59% today. Year to date, PYXS is +46.96%; over the trailing twelve months it is -51.16%. Its 52-week range spans $0.83 to $5.55. Analyst consensus is strong buy with an average price target of $9.00. Rallies surfaces PYXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GordonMD Global Investments reports $16 million Pyxis Oncology common share purchase: GordonMD Global Investments disclosed buying 5,517,000 Pyxis Oncology common shares, bringing its beneficial ownership to 15,541,909 shares. The filing also reports a purchase of 7,546,766 warrants with a $3.50 exercise price; they are not exercisable until stockholder approval increases authorized common shares.
| Metric | Value |
|---|---|
| Price | $1.69 |
| Market Cap | $140.13M |
| P/E Ratio | -1.57 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.55 |
| 52-Week Low | $0.83 |
| Volume | 34.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $11.04M |
| Net Income | $-88.73M |
| Gross Margin | 0.00% |
7 analysts cover PYXS: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.00.